This observational study is looking at how the immune system around breast cancer cells might affect how well treatments work. Researchers will collect personal health information and breast cancer tissue samples from women treated at the University of Pennsylvania. They will compare the immune environments of ER+HER2- (estrogen receptor positive, HER2 negative) breast cancers with triple-negative and HER2+ breast cancers. This study is for women aged 18 or older with non-metastatic breast cancer who are having surgery at the University of Pennsylvania Health System. The main goal is to collect and store these tissue samples. The study status is currently unclear.

Study design

This is an observational case-control study, meaning researchers will compare groups of participants without giving new treatments. Around 300 women are planned to participate.

What's involved

You would allow researchers to collect your personal health information and breast cancer tumor tissues. This collection would happen through study completion, which averages 2 years.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint involves collecting, processing, and archiving breast cancer tumor tissues through study completion, which averages 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.